Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Frontiers in Oncology|January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
Leukemia & Lymphoma|February 28, 2020
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemiaGail J Roboz, Melissa L Larson, S Eric Rubenstein, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Clinical Journal of Oncology Nursing|March 19, 2017
Tools for Communication: Novel infrastructure to address patient-perceived gaps in oncology care
Suzanne McMullen, Shelagh Szabo, Ronald J Halbert, et al.
Journal of Clinical Apheresis|June 3, 2015
Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantationKyle R Brownback, Steven Q Simpson, Lucas R Pitts, et al.
Hematological Oncology|September 9, 2021
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemiaKimberley Doucette, Mary-Elizabeth Percival, Lacey Williams, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2022
Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19Michael R Cook, Kaitlyn Dykes, Katherine White, et al.
Plos One|January 5, 2011
Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926Tara L Lin, Qiuju H Wang, Patrick Brown, et al.
Contemporary Clinical Trials Communications|February 29, 2024
Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer centerXiaosong Shi, Dinesh Pal Mudaranthakam, Jo A Wick, et al.
Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Pageof 15